KU Leuven-ko ikertzaileekin lankidetzan egindako argitalpenak (52)

2024

  1. A plain language summary of the PERSEUS study of daratumumab plus bortezomib, lenalidomide, and dexamethasone for treating newly diagnosed multiple myeloma

    Future Oncology

  2. Belantamab mafodotin: an important treatment option for vulnerable patients with triple class exposed relapsed and/or refractory multiple myeloma

    Haematologica

  3. Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.

    New England Journal of Medicine, Vol. 390, Núm. 4, pp. 301-313

  4. Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens: patient-reported outcomes from the phase 3, randomised, open-label KarMMa-3 clinical trial

    The Lancet Haematology, Vol. 11, Núm. 3, pp. e216-e227

  5. Ide-cel vs standard regimens in triple-class–exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses

    Blood

  6. Plain language summary of the KarMMa-3 study of ide-cel or standard of care regimens in people with relapsed or refractory multiple myeloma

    Future Oncology, Vol. 20, Núm. 18, pp. 1221-1235

  7. Teclistamab Improves Patient-Reported Symptoms and Health-Related Quality of Life in Relapsed or Refractory Multiple Myeloma: Results From the Phase II MajesTEC-1 Study

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 24, Núm. 3, pp. 194-202

2023

  1. An indirect treatment comparison of efficacy and health-related quality of life following treatment with idecabtagene vicleucel versus belantamab mafodotin in triple-class exposed relapsed/refractory patients with multiple myeloma

    Leukemia and Lymphoma

  2. Analysis of patient-reported experiences up to 2 years after receiving idecabtagene vicleucel (ide-cel, bb2121) for relapsed or refractory multiple myeloma: Longitudinal findings from the phase 2 KarMMa trial

    Leukemia Research, Vol. 129

  3. Correction: “The 5th edition of The World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms” Leukemia. 2022 Jul;36(7):1720–1748 (Leukemia, (2022), 36, 7, (1720-1748), 10.1038/s41375-022-01620-2)

    Leukemia

  4. Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma.

    New England Journal of Medicine, Vol. 388, Núm. 11, pp. 1002-1014

  5. Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN)

    Leukemia, Vol. 37, Núm. 6, pp. 1175-1185

  6. Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network

    The Lancet Oncology, Vol. 24, Núm. 6, pp. e255-e269

2022

  1. Corrigendum to 'Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up': [Ann Oncol 2021; 32(3): 309-322

    Annals of oncology : official journal of the European Society for Medical Oncology

  2. Corrigendum: “Corrigendum to ‘Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up’”: (Annals of Oncology (2022) 33(1) (117), (S0923753421044999), (10.1016/j.annonc.2021.10.001))

    Annals of Oncology

  3. Health-related quality of life with idecabtagene vicleucel in relapsed and refractory multiple myeloma

    Blood Advances

  4. LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma

    Leukemia, Vol. 36, Núm. 5, pp. 1371-1376

  5. Patient experience before and after treatment with idecabtagene vicleucel (ide-cel, bb2121): qualitative analysis of patient interviews in the KarMMa trial

    Leukemia Research, Vol. 120

  6. Predictors of use of direct oral anticoagulants in patients with venous thromboembolism: Findings from the Registro Informatizado Enfermedad Tromboembólica registry

    Frontiers in Medicine, Vol. 9

  7. Teclistamab in Relapsed or Refractory Multiple Myeloma

    New England Journal of Medicine, Vol. 387, Núm. 6, pp. 495-505